Selecting A CDMO For Custom Activated PEGs

PEGylation has become a cornerstone of modern drug development, offering a reliable way to enhance pharmacokinetics, reduce immunogenicity, and improve delivery across biological barriers. Yet turning PEGylation’s benefits into a successful therapeutic requires far more than selecting a polymer. This white paper explores the strategic considerations behind choosing the right CDMO for custom-activated PEGs, from functionalization options and analytical requirements to regulatory classification and GMP readiness. Gain insight into when to move beyond off‑the‑shelf materials, how custom PEGs support late‑stage development, and why comprehensive analytical control is essential for managing impurities and achieving reproducible conjugation.

Access the full white paper to dive deeper into best practices and CDMO selection criteria.